2658-6533Research Results in Biomedicine2658-653310.18413/2313-8955-2015-1-3-104-111480Archive categoriesDEVELOPMENT AND VALIDATION OF METHODS OF QUANTITATIVE DETERMINATION OF IMATINIB IN THE BLOOD PLASMA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH MASS SPECTROMETRIC DETECTIONDEVELOPMENT AND VALIDATION OF METHODS OF QUANTITATIVE DETERMINATION OF IMATINIB IN THE BLOOD PLASMA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH MASS SPECTROMETRIC DETECTIONAvtinaTatiana V.AvtinaTatiana V.avtina_t@bsu.edu.ruPokrovskiiMikhail V.PokrovskiiMikhail V.pokrovskii@bsuedu.ruKulikovAleksandr L.KulikovAleksandr L.kulikov@bsu.edu.ru20151300

The authors have developed a method of quantitative determination of an antitumor agent − a protein kinase inhibitor in the blood plasma by high performance liquid chromatography with tandem mass spectrometric detection. The analytical method range was from 0.03 to 3.83 g / ml in plasma. The method was used for the bioequivalence study of the reconstituted medicine containing imatinib as an active pharmaceutical ingredient compared with the reference.

The authors have developed a method of quantitative determination of an antitumor agent − a protein kinase inhibitor in the blood plasma by high performance liquid chromatography with tandem mass spectrometric detection. The analytical method range was from 0.03 to 3.83 g / ml in plasma. The method was used for the bioequivalence study of the reconstituted medicine containing imatinib as an active pharmaceutical ingredient compared with the reference.

imatinibblood plasmahigh performance liquid chromatographyMass spectrometric detectorvalidationimatinibblood plasmahigh performance liquid chromatographyMass spectrometric detectorvalidationСписок литературыMironov A.N. The Guidelines for Expertise of Medicines, T. I. M.: Grif and K, 2013. 322 p.The Federal Law of April 12, 201 (ed. of 07.13.2015) №61 of the Federal Law "On Circulation of Medicines" // Rossiiskaya Gazeta, April 14, 2010 №5157.Gomes AL, Bardales RH Molecular analysis of c-KIT and PDGFRA in GISTs diagnosed by EUS // Am J Clin Pathol. 2007. Jan; 127 (1). P. 89-96.Guidance for Industry: Bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER), US Government Printing Office, Washington, DC (2001).Joensuu H, et al. Twelve vs. 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII / AIO). 47th Annual Meeting of the American Society of Clinical Oncology. Abstract No. LBA1. June 5, 2011.Pediatric oncology subcommittee of the oncology drugs advisory committee (ODAC) meeting [electronic resource] URL: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm330208.pdf (date of access December 3, 2015).